The serum half-life of a drug can be increased by conjugation to various entities.^[@cit1]^ In general, strategies operate by increasing the size of the overall construct to minimise renal clearance or through enabling recycling *via* the neonatal Fc receptor (FcRn).^[@cit1]^ Thus, human serum albumin is an excellent conjugation candidate for serum half-life extension as it offers both of these features (*t* ~1/2~ albumin ≈ 19 days).^[@cit2]^ Accordingly the use of albumin for drug delivery has been proven in the clinic and GSK has launched Eperzan® (2014), which is an albumin-GLP-1 fusion for the treatment of type 2 diabetes mellitus in adults.^[@cit2],[@cit3]^

Owing to the favourable properties of albumin, various strategies have been employed to extend the circulatory half-life of numerous entities by engaging them covalently or transiently with this protein.^[@cit2]^ As albumin has a single free thiol (cysteine 34) available for conjugation, covalent conjugation *via* reaction at this position has proved to be a very popular strategy for attachment.^[@cit2]^ This strategy has been used to extend the half-life of various protein-based drugs, including granulocyte colony stimulating factor (G-CSF),^[@cit4]^ Kringle domain,^[@cit5]^ DARPin domain,^[@cit6]^ the antiretroviral gp41 targeting peptide C34 (PC-1505),^[@cit7]^ insulin,^[@cit8]^ the opioid agonist dynorphin A (CJC-1008),^[@cit9]^ YY peptide^[@cit10]^ and GLP-1/exendin-4 (CJC-1131 and CJC-1134-PC).^[@cit11]^ Lysine modification strategies have also been trialled,^[@cit2]^ however, these approaches result in hetereogeneous mixtures (due to a large number of surface accessible lysines on albumin), limit solubility (by removal of charged groups) and may result in denaturing.^[@cit12]^

Cysteine 34 is located close to the surface of the albumin protein in a shallow crevice ([Fig. 1](#fig1){ref-type="fig"}). It is situated in a rather anionic environment and has relatively limited solvent accessibility.^[@cit2],[@cit13]^ This environment infers some unique properties on the thiol, and it has a p*K* ~a~ of approximately 8.5 in the absence of external factors *in vivo*.^[@cit13]^

![Structure of albumin, highlighting cysteine 34 and key features.](c5ob01205h-f1){#fig1}

Historically, for conjugation to a free thiol on cysteine, maleimide chemistry has been used. Thus, it is no surprise that maleimides have been shown to react with the thiolate of cysteine 34 of albumin **1** in an efficient manner to form succinimide-albumin conjugates, **2** ([Scheme 1](#sch1){ref-type="fig"}).^[@cit2],[@cit4]--[@cit11]^ A pH of 7.4 is generally used to ensure that there is enough of the thiolate available whilst minimizing deprotonation of ammonium groups, *i.e.* to perturb side-reactions of the protein amino groups with maleimide. However, it has recently come to light that the thioether bond on the resultant succinimide is not robust.^[@cit14]^ The succinimide can revert back to maleimide and free thiol *via* a retro-Michael pathway. Thus, highly undesirably, the released maleimide may react with other thiol reactive species and the released thiol may react with other compounds *in vivo*.^[@cit14]^

![Classical approach to albumin conjugation, highlighting limitations and alternative pathways.](c5ob01205h-s1){#sch1}

To avoid retro-Michael reactivity, the succinimide may be hydrolysed to succinic acid **3**, effectively locking the conjugate to be thiol-stable.^[@cit15]^ The property of thiol-stability by hydrolysis is desirable as it would ensure that there was no undesirable thiol transfer taking place in various environments *in vivo*. To this end, we constructed bioconjugate **2** (R = Me) and attempted to selectively hydrolyse the succinimide ring under a range of hydrolysis conditions (*e.g.* temperature and pH). However, the yield of the hydrolysed thiol-stable conjugate was only in the order of 50--60% due to a competing retro-Michael pathway during hydrolysis (see ESI[†](#fn1){ref-type="fn"} and [Fig. 2](#fig2){ref-type="fig"}). Although retro-Michael deconjugation affords the starting materials initially, the free maleimide is also hydrolysed irreversibly under the reaction conditions, which limits yield (see [Scheme 1](#sch1){ref-type="fig"}). Strategies have been developed to address this issue but they require highly specific linkers and their success tends to be protein and protein local microenvironment specific.^[@cit15]^

![Deconvoluted mass spectrum obtained upon attempted hydrolysis of conjugate **2** at pH 9 showing a mixture of albumin **1** and conjugate **3**.](c5ob01205h-f2){#fig2}

To supersede conventional maleimide-bioconjugation we would require a moiety that did not suffer from competing retro-Michael mediated deconjugation during hydrolysis whilst retaining the favourable characteristics of efficient and chemoselective reaction with maleimides. To this end, we set about exploring monobromomaleimides in this context.^[@cit16]^ Our choice of using monobromomaleimides was motivated mainly by the fact that reaction with a thiol proceeds *via* an addition-elimination sequence, *i.e.* rather than addition only. This affords a thioether maleimide motif, for which the retro-Michael pathway is no longer mechanistically feasible ([Fig. 3](#fig3){ref-type="fig"}). Our study began by appraising the efficiency and selectivity of conjugation with a monobromomaleimide. We were delighted to find that *N*-methyl monobromomaleimide reacted within the same time-frame and with the same specificity as a classical maleimide ([Fig. 3b](#fig3){ref-type="fig"}, see ESI[†](#fn1){ref-type="fn"} for further details).

![(a) Conjugation of *N*-methyl monobromomaleimide to albumin to form bioconjugate **4**, and subsequent hydrolysis to afford **5**; (b) deconvoluted MS data for maleimide--albumin bioconjugate **4**; (c) deconvoluted MS data for maleamic acid-albumin bioconjugate **5**.](c5ob01205h-f3){#fig3}

We next treated thioether maleimide conjugate **4** under basic conditions to see if we only observed hydrolysed product **5**. Gratifyingly, this was the only product that was observed under the reaction conditions, thus providing an elegant and simple solution to making a thiol-stable construct on albumin. The rate of hydrolysis was similar to that observed for the succinimide analogue.

To confirm the absence of thiol reactivity of maleamic acid-albumin bioconjugate **5**, it was incubated with 50 equivalents of glutathione (1 mM) at pH 7.4 in PBS ([Fig. 4](#fig4){ref-type="fig"}) for 4 h. Consistent with our previous studies, no thiol exchange was observed after incubation.^[@cit16a]^ In fact, no significant transfer was observed even after 95 h. This is in sharp contrast to succinimide bioconjugate **2** (where R = Me), where significant thiol exchange was observed after 4 h (see ESI[†](#fn1){ref-type="fn"}, Fig. S15[†](#fn1){ref-type="fn"}). Actually, the only succinimide conjugate that remained attached to albumin after this time was the hydrolysed construct, which is known to be thiol stable.^[@cit15]^

![(a) Thiol stability of maleamic acid--albumin bioconjugate **5**; (b) deconvoluted MS data for maleamic acid-albumin bioconjugate **5** after 4 hours of incubation; and (c) deconvoluted MS data for maleamic acid-albumin bioconjugate **5** after 95 hours of incubation.](c5ob01205h-f4){#fig4}

Following our work on developing a thiol stable construct, we set about incorporating simple, modular 'click' chemistry into our strategy through the use of *N*-propargyl monobromomaleimide and Alexa Fluor® 488 azide (see [Scheme 2](#sch2){ref-type="fig"}, see ESI[†](#fn1){ref-type="fn"} for further details). If successful, this would result in a facile method for forming various thiol-stable functional bioconjugates. Pleasingly, clicking *N*-propargyl monobromomaleimide with Alexa Fluor® 488 azide followed by conjugation to albumin **1** afforded bioconjugate **6** by MS and UV-Vis absorption. This species was then hydrolysed to thiol-stable bioconjugate **7** without any deconjugation, thus highlighting how our platform can incorporate a 'click' modification strategy.

![Click functionalisation strategy for creating thiol-stable albumin conjugate **7**.](c5ob01205h-s2){#sch2}

Conclusions
===========

In conclusion, an elegant, robust, high yielding and thiol-stable alternative to classical maleimide conjugation to human serum albumin has been described. Classical maleimide conjugation has been shown to be reversible and methods for hydrolysis to thiol-stable thioether succinimides were shown to be unsuccessful as they led to significant retro-Michael mediated deconjugation. The use of monobromomaleimides results in rapid and selective conjugation, and hydrolysis leads to thiol-stable maleamic acid only, due to the absence of a retro-Michael pathway mechanistically. The exemplification of the chemistry *via* a 'click' strategy highlights how it may be readily utilised in various applications in a rapid manner. As well as providing a general, efficient approach to creating thiol-stable cysteine conjugates, this works sets the foundation for a platform for half-life extension by the use of stable human serum albumin conjugation.
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[^1]: †Electronic supplementary information (ESI) available: LC-MS, ES-MS and deconvoluted spectra for all reactions with proteins described herein, and ^1^H and ^13^C NMR spectra for all small molecule constructs. See DOI: [10.1039/c5ob01205h](10.1039/c5ob01205h) Click here for additional data file.
